Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Insights: "FeDeriCa Trial Final Analysis - Fixed-Dose Combination of Pertuzumab & Trastuzumab for Subcutaneous Injection + Chemo in HER2+ eBC"
Login to view comments.
Click here to Login
Videos